Mizuho maintains Neutral on Revance, price target at $3.65
Securities maintained its Neutral rating on Revance Therapeutics (NASDAQ:RVNC) with a steady price target of $3.65, closely ...
Geneos Wealth Management Inc. Has $253,000 Holdings in The Clorox Company (NYSE:CLX)
Geneos Wealth Management Inc. lessened its holdings in shares of The Clorox Company (NYSE:CLX – Free Report) by 8.3% during ...
MarketWatch17d
Investors have 'a false sense of security' around 5% peak Treasury yields, says Mizuho
Yet "the bond market has not taken on board" the potential for 3% inflation in 2025, Steven Ricchiuto, chief economist at Mizuho Securities, wrote in a Monday client note. Even before December's ...
Seeking Alpha6d
Qorvo in focus as Mizuho ups estimates on activist involvement
Qorvo (NASDAQ:QRVO) shares fell 0.5% in premarket trading on Friday, even as Mizuho Securities upped its earnings estimates on the involvement of activist investor Starboard Value. Mizuho analyst ...
Yahoo Finance12d
Mizuho Financial Group, Inc. (MFG)
This year’s winners from Mizuho Americas were: Serena Lin, Managing Director and Head of Agency Mortgage-Backed Securities Trading Desk for Excellence in Fix NEW YORK, Aug. 28, 2024 (GLOBE ...
The TRADE10d
KNG Securities taps Mizuho for new emerging markets fixed income specialist
Incoming individual brings 30 years’ experience in emerging markets debt to the role, having previously held positions at Mizuho International, VTB Capital, BNP Paribas, ING Nederland and CIBC World ...
Seeking Alpha22d
Mizuho upgrades Vornado Realty, Cousins Properties, downgrades Kilroy
Mizuho Securities raised its recommendation on Vornado Realty Trust (NYSE:VNO) and Cousins Properties (NYSE:CUZ), and downgraded Kilroy Realty (NYSE:KRC), considering their geographic exposure and ...
Mizuho maintains neutral on Revance, price target steady at $3.65
Mizuho (NYSE:MFG) analysts maintained a Neutral rating on Revance Therapeutics (NASDAQ:RVNC), a $382 million market cap company, with a steady price target of $3.65. The firm's stance came in the wake ...